Display options
Cite
Hisahara S, Shimohama S. Dopamine receptors and Parkinson's disease. Int J Med Chem. 2011;2011:403039doi: 10.1155/2011/403039.
Hisahara, S., & Shimohama, S. (2011). Dopamine receptors and Parkinson's disease. International journal of medicinal chemistry, 2011403039. https://doi.org/10.1155/2011/403039
Hisahara, Shin, and Shimohama, Shun. "Dopamine receptors and Parkinson's disease." International journal of medicinal chemistry vol. 2011 (2011): 403039. doi: https://doi.org/10.1155/2011/403039
Hisahara S, Shimohama S. Dopamine receptors and Parkinson's disease. Int J Med Chem. 2011;2011:403039. doi: 10.1155/2011/403039. Epub 2011 Jun 13. PMID: 25954517; PMCID: PMC4411877.
Copy Download .nbib Format: NLM
Share it on

Int J Med Chem. 2011;2011:403039. doi: 10.1155/2011/403039. Epub 2011 Jun 13.

Dopamine receptors and Parkinson's disease.

International journal of medicinal chemistry

Shin Hisahara, Shun Shimohama

Affiliations

  1. Department of Neurology, Sapporo Medical University, Sapporo 060-8556, Japan.

PMID: 25954517 PMCID: PMC4411877 DOI: 10.1155/2011/403039

Abstract

Parkinson's disease (PD) is a progressive extrapyramidal motor disorder. Pathologically, this disease is characterized by the selective dopaminergic (DAergic) neuronal degeneration in the substantia nigra. Correcting the DA deficiency in PD with levodopa (L-dopa) significantly attenuates the motor symptoms; however, its effectiveness often declines, and L-dopa-related adverse effects emerge after long-term treatment. Nowadays, DA receptor agonists are useful medication even regarded as first choice to delay the starting of L-dopa therapy. In advanced stage of PD, they are also used as adjunct therapy together with L-dopa. DA receptor agonists act by stimulation of presynaptic and postsynaptic DA receptors. Despite the usefulness, they could be causative drugs for valvulopathy and nonmotor complication such as DA dysregulation syndrome (DDS). In this paper, physiological characteristics of DA receptor familyare discussed. We also discuss the validity, benefits, and specific adverse effects of pharmaceutical DA receptor agonist.

References

  1. Neurology. 1993 Dec;43(12 Suppl 6):S23-7 - PubMed
  2. Brain Res. 1994 Sep 19;657(1-2):207-13 - PubMed
  3. J Biol Chem. 2004 Aug 20;279(34):35671-8 - PubMed
  4. J Neural Transm (Vienna). 2010 Apr;117(4):463-73 - PubMed
  5. Neuroreport. 2000 Aug 3;11(11):2395-9 - PubMed
  6. Neurobiol Aging. 1992 Mar-Apr;13(2):339-51 - PubMed
  7. Pharmacol Biochem Behav. 1991 Jan;38(1):147-54 - PubMed
  8. Mov Disord. 2007 Jan 15;22(2):213-9 - PubMed
  9. J Neurochem. 2004 Dec;91(5):1075-81 - PubMed
  10. Cell. 1994 Nov 18;79(4):729-42 - PubMed
  11. Trends Pharmacol Sci. 2007 Apr;28(4):166-72 - PubMed
  12. Nature. 1989 Dec 21-28;342(6252):923-6 - PubMed
  13. Mov Disord. 2004 Jun;19(6):656-62 - PubMed
  14. Psychopharmacology (Berl). 2002 Feb;159(4):370-8 - PubMed
  15. Adv Exp Med Biol. 2004;541:55-74 - PubMed
  16. Neuron. 1997 Oct;19(4):837-48 - PubMed
  17. Neurology. 2006 Oct 10;67(7):1254-7 - PubMed
  18. Lancet. 2004 Apr 10;363(9416):1179-83 - PubMed
  19. J Neurosci. 2000 Dec 15;20(24):8987-95 - PubMed
  20. Mov Disord. 2006 Dec;21(12):2214-7 - PubMed
  21. Trends Neurosci. 2007 May;30(5):211-9 - PubMed
  22. Mov Disord. 2005 May;20(5):523-39 - PubMed
  23. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8861-5 - PubMed
  24. J Neurochem. 1994 Mar;62(3):1034-8 - PubMed
  25. Lancet. 1995 Oct 28;346(8983):1130-1 - PubMed
  26. J Neurosci. 1998 Dec 15;18(24):10553-65 - PubMed
  27. Eur J Pharmacol. 2007 Feb 28;557(2-3):132-40 - PubMed
  28. Mov Disord. 2006 Aug;21(8):1261-4 - PubMed
  29. Neurosci Lett. 2010 Nov 26;485(3):256-60 - PubMed
  30. Nature. 1978 May 4;273(5657):59-61 - PubMed
  31. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74 - PubMed
  32. Clin Neuropharmacol. 2003 May-Jun;26(3):146-50 - PubMed
  33. Mov Disord. 2010 Feb 15;25(3):368-76 - PubMed
  34. Annu Rev Neurosci. 2000;23:185-215 - PubMed
  35. Neuropharmacology. 1996;35(11):1503-19 - PubMed
  36. J Neurosci. 2000 Aug 1;20(15):5848-52 - PubMed
  37. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):115-27 - PubMed
  38. CNS Neurosci Ther. 2008 Fall;14(3):248-62 - PubMed
  39. Eur J Pharmacol. 2005 Apr 25;513(3):225-8 - PubMed
  40. Brain Res. 2000 Nov 17;883(2):216-23 - PubMed
  41. JAMA. 2002 Apr 3;287(13):1653-61 - PubMed
  42. Curr Opin Neurol. 2003 Dec;16 Suppl 1:S9-12 - PubMed
  43. Arch Neurol. 2007 Feb;64(2):212-6 - PubMed
  44. Exp Neurol. 2007 Feb;203(2):415-22 - PubMed
  45. Pharmacology. 2004 Jul;71(3):162-8 - PubMed
  46. Parkinsonism Relat Disord. 2005 Sep;11(6):381-6 - PubMed
  47. Trends Neurosci. 2007 May;30(5):228-35 - PubMed
  48. Eur J Neurol. 2002 May;9(3):253-7 - PubMed
  49. Brain Res. 2004 Nov 5;1026(1):95-107 - PubMed
  50. Neurology. 2006 Sep 26;67(6):1034-9 - PubMed
  51. J Neural Transm (Vienna). 2006 Sep;113(9):1107-18 - PubMed
  52. Brain. 2009 May;132(Pt 5):1366-75 - PubMed
  53. Psychopharmacology (Berl). 1999 Nov;147(2):143-52 - PubMed
  54. J Neurosci Res. 2002 Feb 15;67(4):494-500 - PubMed
  55. N Engl J Med. 2007 Jan 4;356(1):39-46 - PubMed
  56. Nature. 1979 Jan 11;277(5692):93-6 - PubMed
  57. Ann N Y Acad Sci. 1994 Nov 17;738:222-9 - PubMed
  58. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2715-8 - PubMed
  59. Mayo Clin Proc. 2002 Dec;77(12 ):1280-6 - PubMed
  60. Annu Rev Neurosci. 1992;15:285-320 - PubMed
  61. CNS Drugs. 2003;17(13):965-73 - PubMed
  62. N Engl J Med. 2007 Jan 4;356(1):29-38 - PubMed
  63. Brain Res. 1999 Aug 14;838(1-2):51-9 - PubMed
  64. J Psychiatry Neurosci. 1992 Oct;17(4):158-80 - PubMed
  65. Neurology. 2005 Dec 29;65(12 Suppl 4):S3-6 - PubMed
  66. Eur J Pharmacol. 1996 Jul 18;308(2):219-25 - PubMed
  67. Lancet Neurol. 2007 Jun;6(6):513-20 - PubMed
  68. Neurology. 1999 Jul 22;53(2):364-70 - PubMed
  69. Neurosci Biobehav Rev. 2000 Jan;24(1):125-32 - PubMed
  70. Eur J Pharmacol. 1985 Jul 31;113(3):467-8 - PubMed
  71. Mov Disord. 2004 Dec;19(12):1523-4 - PubMed
  72. J Neural Transm Suppl. 1995;45:307-18 - PubMed
  73. Behav Pharmacol. 1994 Apr;5(2):141-152 - PubMed
  74. Eur J Neurosci. 2002 Jan;15(1):158-64 - PubMed
  75. Mol Cell Neurosci. 1998 Dec;12(6):390-402 - PubMed
  76. J Neurosci. 1995 Dec;15(12):7821-36 - PubMed
  77. Pract Neurol. 2007 Nov;7(6):397-9 - PubMed
  78. Cell. 1997 Sep 19;90(6):991-1001 - PubMed
  79. Mov Disord. 2002 Nov;17(6):1371-4 - PubMed
  80. Life Sci. 1999;64(15):1275-85 - PubMed
  81. J Biol Chem. 2002 Nov 29;277(48):46010-9 - PubMed
  82. Mov Disord. 2003 Apr;18(4):418-25 - PubMed
  83. Psychopharmacology (Berl). 2008 Jan;196(1):39-49 - PubMed
  84. Drugs Aging. 2001;18(6):389-96 - PubMed
  85. Lancet Neurol. 2008 Jul;7(7):595-604 - PubMed
  86. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4182-7 - PubMed
  87. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86 - PubMed
  88. J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):423-8 - PubMed
  89. Science. 2001 Nov 2;294(5544):1021-4 - PubMed
  90. Eur J Pharmacol. 1992 May 14;215(2-3):161-70 - PubMed
  91. J Med Chem. 2005 Feb 10;48(3):839-48 - PubMed
  92. J Neurosci. 1998 May 1;18(9):3470-9 - PubMed
  93. J Comp Neurol. 2002 Jan 21;442(4):392-404 - PubMed
  94. J Neurosci. 1995 Jul;15(7 Pt 2):5222-37 - PubMed
  95. J Neural Transm Suppl. 1995;45:297-305 - PubMed
  96. Mov Disord. 2001 May;16(3):507-10 - PubMed
  97. J Neurochem. 2001 Feb;76(4):990-7 - PubMed
  98. Eur J Neurol. 2003 Jul;10(4):399-406 - PubMed
  99. J Neurosci. 2002 Jul 1;22(13):5619-29 - PubMed
  100. Nature. 1995 Oct 5;377(6548):424-8 - PubMed
  101. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12564-8 - PubMed
  102. J Neurosci. 2003 Sep 17;23(24):8506-12 - PubMed
  103. Eur J Pharmacol. 2003 Aug 15;475(1-3):29-35 - PubMed
  104. Neuroreport. 1998 Aug 24;9(12):2857-60 - PubMed
  105. Free Radic Biol Med. 1993 Aug;15(2):159-67 - PubMed
  106. Arch Neurol. 2005 Aug;62(8):1290-5 - PubMed
  107. J Epidemiol. 2009;19(6):281-93 - PubMed
  108. Sleep Med. 2008 Mar;9(3):228-39 - PubMed
  109. N Engl J Med. 2005 Nov 3;353(18):1976-7 - PubMed
  110. J Biol Chem. 2000 Dec 8;275(49):38944-8 - PubMed
  111. Arch Int Pharmacodyn Ther. 1995 Mar-Apr;329(2):221-30 - PubMed
  112. Cardiol Rev. 2002 Nov-Dec;10(6):334-6 - PubMed
  113. Nature. 1989 Dec 21-28;342(6252):926-9 - PubMed
  114. Sleep. 2004 Aug 1;27(5):907-14 - PubMed
  115. Am J Pathol. 2002 Dec;161(6):2111-21 - PubMed
  116. Mov Disord. 2007 Jan 15;22(2):234-8 - PubMed
  117. Neurology. 2006 Jun 13;66(11):1750-2 - PubMed
  118. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804 - PubMed
  119. Parkinsonism Relat Disord. 2001 Apr;7(2):115-120 - PubMed
  120. Neuroscience. 1995 Apr;65(3):709-30 - PubMed
  121. Cell. 2005 Jul 29;122(2):261-73 - PubMed
  122. Arch Gen Psychiatry. 1997 Jun;54(6):567-72 - PubMed
  123. Neuropharmacology. 2002 Mar;42(3):367-73 - PubMed
  124. Prog Brain Res. 1990;85:95-116; discussion 116-8 - PubMed
  125. J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76 - PubMed
  126. J Neurosci. 2000 Mar 15;20(6):2369-82 - PubMed
  127. J Neurosci. 1996 Aug 1;16(15):4707-15 - PubMed
  128. J Neural Transm (Vienna). 2002 May;109(5-6):633-43 - PubMed
  129. Neurology. 2003 Sep 23;61(6 Suppl 3):S34-42 - PubMed
  130. Mol Pharmacol. 2009 Mar;75(3):447-53 - PubMed
  131. Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):654-9 - PubMed
  132. Neuropsychopharmacology. 2003 Apr;28(4):787-94 - PubMed
  133. Acta Pharmacol Toxicol (Copenh). 1963;20:140-4 - PubMed
  134. Proc Natl Acad Sci U S A. 1986 Feb;83(3):674-8 - PubMed
  135. Circulation. 2006 Jan 3;113(1):81-9 - PubMed
  136. Ann Neurol. 1998 Jul;44(1):110-9 - PubMed
  137. Physiol Rev. 1998 Jan;78(1):189-225 - PubMed
  138. J Pharmacol Exp Ther. 1989 Jan;248(1):171-5 - PubMed
  139. J Neuropsychiatry Clin Neurosci. 2005 Spring;17(2):214-20 - PubMed
  140. Clin Neuropharmacol. 2006 May-Jun;29(3):112-25 - PubMed
  141. Drugs Aging. 2004;21(11):687-709 - PubMed
  142. J Neurosci. 1997 Jun 15;17(12):4536-44 - PubMed
  143. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1945-9 - PubMed
  144. J Neurosci Res. 2002 Nov 1;70(3):274-82 - PubMed
  145. J Neurosci. 1994 Jan;14(1):88-106 - PubMed
  146. FASEB J. 1990 Jul;4(10):2737-44 - PubMed
  147. Neuropharmacology. 1996 Mar;35(3):285-94 - PubMed
  148. Neuroscience. 1999;91(3):911-24 - PubMed
  149. Brain Res. 2007 Jul 30;1160:113-23 - PubMed
  150. Eur J Neurosci. 2005 Oct;22(7):1741-50 - PubMed
  151. Neurochem Res. 2009 Feb;34(2):327-32 - PubMed
  152. Mov Disord. 2004 Dec;19(12):1522-3 - PubMed
  153. J Pharmacol Exp Ther. 2006 Nov;319(2):914-23 - PubMed
  154. J Neurosci. 2000 Nov 15;20(22):8305-14 - PubMed
  155. J Neurosci. 1999 Nov 1;19(21):9550-6 - PubMed
  156. Eur J Clin Pharmacol. 1984;27(3):335-9 - PubMed
  157. Brain. 1999 Aug;122 ( Pt 8):1437-48 - PubMed
  158. N Engl J Med. 2000 May 18;342(20):1484-91 - PubMed
  159. CNS Drugs. 2004;18(11):747-54; discussion 755-6 - PubMed
  160. Mol Pharmacol. 2002 Jul;62(1):119-26 - PubMed
  161. Mov Disord. 1999 Jul;14(4):612-8 - PubMed
  162. Brain Res Mol Brain Res. 1992 Jul;14(3):186-95 - PubMed
  163. J Pharmacol Exp Ther. 1995 Nov;275(2):885-98 - PubMed
  164. Ann Neurol. 2009 Oct;66(4):472-84 - PubMed
  165. Pharmacol Rev. 1980 Sep;32(3):229-313 - PubMed
  166. Neuroscience. 2008 Jul 31;155(1):53-63 - PubMed
  167. Brain Res. 1998 Nov 9;810(1-2):27-33 - PubMed
  168. Neurosci Res. 2002 Jul;43(3):259-67 - PubMed
  169. Front Neuroanat. 2010 Jun 14;4:21 - PubMed
  170. N Engl J Med. 2007 Jan 4;356(1):6-9 - PubMed
  171. Neurochem Res. 2003 Jul;28(7):1035-40 - PubMed
  172. Science. 1986 Dec 19;234(4783):1558-63 - PubMed
  173. Mov Disord. 2006 Aug;21(8):1109-13 - PubMed
  174. J Pharmacol Exp Ther. 2010 Nov;335(2):506-15 - PubMed
  175. Nature. 1988 Sep 15;335(6187):254-6 - PubMed
  176. Neurology. 2007 Jan 23;68(4):272-6 - PubMed
  177. J Neural Transm (Vienna). 1996;103(11):1307-16 - PubMed
  178. J Pharmacol Exp Ther. 1995 Nov;275(2):899-913 - PubMed
  179. Brain. 2004 Jun;127(Pt 6):1332-42 - PubMed
  180. Prog Neurobiol. 2004 Sep;74(1):1-58 - PubMed
  181. J Pharmacol Exp Ther. 2002 Nov;303(2):815-22 - PubMed
  182. Mov Disord. 1994 Mar;9(2):147-54 - PubMed
  183. J Neurophysiol. 1997 Feb;77(2):1003-15 - PubMed
  184. Annu Rev Pharmacol Toxicol. 2004;44:269-96 - PubMed
  185. Acta Neuropathol. 1993;85(4):404-13 - PubMed
  186. Nat Rev Neurosci. 2010 May;11(5):301-15 - PubMed
  187. Exp Toxicol Pathol. 2008 Aug;60(4-5):253-62 - PubMed
  188. Mov Disord. 2006 Dec;21(12):2110-5 - PubMed
  189. Neurology. 2006 Oct 10;67(7):1225-9 - PubMed
  190. Nihon Shinkei Seishin Yakurigaku Zasshi. 1998 Jun;18(3):81-7 - PubMed
  191. Ann N Y Acad Sci. 1999;890:7-25 - PubMed

Publication Types